We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Toxoplasma Test Added to Benchtop Analyzer's Detection Portfolio

By LabMedica International staff writers
Posted on 16 Sep 2013
A major advance in the detection of infection by the parasite Toxoplasma gondii was marked by release of a molecular diagnostic kit for use in a sophisticated benchtop analyzer.

DiaSorin (Saluggia, Italy) has recently introduced a dedicated assay for T. More...
gondii for use on its Liaison Iam instrument, which is based on proprietary Q-LAMP isothermal amplification technology.

This technology offers all the benefits of isothermal LAMP (Loop Mediated Isothermal Amplification) but with the addition of real time, fluorescent, multiplexed amplification. In addition, Q-LAMP provides for single tube RNA amplification without the need for a reverse transcription step. With multiple recognition events per reaction, the DiaSorin Q-LAMP is highly specific and offers sensitivity on a par with real-time PCR. Detection of the amplified products is achieved with Q-Primers, which are labeled with a unique fluorophore that is quenched in the presence of the target sequence. The reduction of fluorescence is used to monitor the reaction and using a concept called time threshold (TT), together with known calibrators, can be used to quantify an unknown sample containing the target sequence.

All DiaSorin Q-LAMP assays are performed on a uniquely designed small footprint, bench top analyzer, the Liaison Iam analyzer. The analyzer is connected to an Iam Control Unit (ICU) via a USB interface. The ICU runs uniquely designed, simple to use software in which a graphical user interface guides the operator through a series of simple set up steps. From one to six instruments can be connected to a single ICU, allowing laboratories to start with a small number of tests and then add units as the workload or test portfolio grows.

“Iam Toxo rapidly confirms toxo infection,” said Paul Eros, global vice president molecular at DiaSorin. “The diagnostic sensitivity of the assay has been proven to be equivalent to PCR but delivers results produced in a fraction of the time that PCR requires. This assay is the latest addition to the unique and rapidly expanding DiaSorin Q-LAMP assay portfolio for our Liaison Iam molecular instrument, an easy-to-use benchtop device, which provides laboratories with a cost-effective, saleable, molecular diagnostic solution. This is a perfect solution for use in laboratory facilities of all sizes, including those that are located close to the patient.”

“DiaSorin Q-LAMP assays provide many advantages,” said Dr. Eros. “They are rapid, real-time, fluorescent, quantitative/qualitative assays designed to be used for multiplexed applications, enabling amplification and detection of multiple targets in a single reaction. Iam Toxo is a duplex fluorescent Q-LAMP assay employing primers designed to recognize a multicopy repeat region of the Toxoplasma gondii genome, common to all clinically-relevant subtypes.”

The Iam Toxo assay, when used with the Liaison Iam instrument, can be used for the detection of all clinically relevant subtypes of T. gondii in human plasma, CSF, and amniotic fluid.

Related Links:
DiaSorin



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.